mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2022-13-1-52-64mvjr-1498Research ArticleЭНДОКРИНОЛОГИЯENDOCRYNOLOGYМолекулярная визуализация и радиотераностика опухолей надпочечниковPersonalized molecular visualization and radiotheranostics of adrenal tumorshttps://orcid.org/0000-0002-2788-2352ОмельчукД. Д.OmelchukD. D.

Ориуэла

Daniil D. Omelchuk – endocrinologist.

Orihuela

lebedev1dd@gmail.comhttps://orcid.org/0000-0001-5652-2607ДегтяревМ. В.DegtyarevM. V.

Дегтярев Михаил Владимирович

Москва

Mikhail V. Degtyarev - Head Department.

Moscow

germed@mail.ruhttps://orcid.org/0000-0002-7721-634XРумянцевП. О.RumyantsevP. O.

Румянцев Павел Олегович - доктор медицинских наук.

Санкт-Петербург

Pavel O. Rumyantsev - Dr. Sci. (Med.), Deputy chief physician, chief oncologist-radiologist of the network of clinics.

Saint-Petersburg

pavelrum@gmail.comОриуэлаSpainНациональный медицинский исследовательский центр эндокринологииРоссияNational Medical Research Center of EndocrinologyRussian FederationМеждународный медицинский центр СОГАЗ-МедицинаРоссияInternational Medical Center SOGAZ-MedicineRussian Federation2022300320221315264Copyright © Омельчук Д.Д., Дегтярев М.В., Румянцев П.О., 20222022Омельчук Д.Д., Дегтярев М.В., Румянцев П.О.Omelchuk D.D., Degtyarev M.V., Rumyantsev P.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/1498

Диагностика опухолей надпочечников улучшилась за последние десятилетия благодаря лабораторным исследованиям и методам анатомической визуализации (УЗИ, КТ, МРТ). В некоторых случаях данные методы позволяют отличить доброкачественную опухоль от злокачественной, а в комбинации с инвазивными методами точность такой диагностики варьируется в пределах от 80 до 100%. Однако в случаях, например, феохромоцитомы или альдостеромы инвазивное вмешательство небезопасно. Гибридные методы молекулярной визуализации, такие как однофотонная эмиссионная томография (ОФЭКТ) и позитронная эмиссионная томография (ПЭТ), совмещённые с КТ или МРТ, являются одновременно методами анатомической и функциональной (молекулярной) визуализации. Методы молекулярной визуализации являются неинвазивными и безопасными для пациентов, а полученная информация позволяет точнее определиться с активностью, прогнозом и тактикой лечения. Целью данного обзора стал анализ современных методов и алгоритмов молекулярной визуализации и радионуклидной терапии новообразований надпочечников. Методы — систематический обзор литературы на базе открытых литературных источников, в том числе собственного опыта. Стратификация полученных данных по механизму действия радиофармпрепаратов, доказательного опыта применения, а также сравнительный анализ эффективности и доступности методов молекулярной визуализации и радионуклидной терапии.

Th e diagnosis of adrenal tumors has improved signifi cantly over the past decades thanks to laboratory research and anatomical imaging techniques. In some cases, these methods make it possible to distinguish a benign tumor from a malignant one, and in combination with invasive methods, the accuracy of such diagnostics varies from 80 to 100%. However, in cases of pheochromocytoma, this invasive intervention can induce a hypertensive crisis. Hybrid molecular imaging techniques such as single-photon emission tomography (SPECT) and positron emission tomography (PET), coupled with CT or MRI, have come to the rescue. Molecular imaging techniques are non-invasive and safe for patients, and the information obtained allows you to more accurately determine the optimal treatment tactics. Purpose: in our review, we will try to cover all modern and promising methods of molecular imaging of adrenal formations and radionuclide therapy, which constitute a new trend in the development of nuclear medicine in the world - radiotheranostics (radionuclide therapy based on radionuclide diagnostics). Methods: We conducted a systematic review of the literature obtained from the open databases Scopus and Pubmed describing the latest methods of radiotherapy of adrenal tumors. We then classifi ed the findings based on mechanism of action, point of application, and relevance of radioactive tracers, comparing their effectiveness and availability.

тераностикамолекулярная визуализацияопухоли надпочечниковфеохромоцитомаальдостеромаОФЭКТ/КТПЭТ/КТtheranosticsmolecular visualizationadrenal tumorspheochromocytomaSPECTreviewReferencesReincke M. Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am. 2000;29(1):43-56. DOI: 10.1016/s0889-8529(05)70115-8Reincke M. Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am. 2000;29(1):43-56. DOI: 10.1016/s0889-8529(05)70115-8Agrawal A, Rangarajan V, Shah S, Puranik A, Purandare N. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies. Br J Radiol. 2018;91(1091):20180103. DOI: 10.1259/bjr.20180103Agrawal A, Rangarajan V, Shah S, Puranik A, Purandare N. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies. Br J Radiol. 2018;91(1091):20180103. DOI: 10.1259/bjr.20180103Vallabhajosula S, Nikolopoulou A. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology. Semin Nucl Med. 2011;41(5):324-33. DOI: 10.1053/j.semnuclmed.2011.05.003Vallabhajosula S, Nikolopoulou A. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology. Semin Nucl Med. 2011;41(5):324-33. DOI: 10.1053/j.semnuclmed.2011.05.003ECopy, Inc. - Food and Drug Administration [Internet]. [cited 2021Dec18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022290s000_ClinPharmR.pdfECopy, Inc. - Food and Drug Administration [Internet]. [cited 2021Dec18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022290s000_ClinPharmR.pdfGreen M, Lowe J, Kadirvel M, McMahon A, Westwood N, et al. Radiosynthesis of no-carrier-added meta-[124I] iodobenzylguanidine for PET imaging of metastatic neuroblastoma. J Radioanal Nucl Chem. 2017;311(1):727732. DOI: 10.1007/s10967-016-5073-1Green M, Lowe J, Kadirvel M, McMahon A, Westwood N, et al. Radiosynthesis of no-carrier-added meta-[124I] iodobenzylguanidine for PET imaging of metastatic neuroblastoma. J Radioanal Nucl Chem. 2017;311(1):727732. DOI: 10.1007/s10967-016-5073-1Hartung-Knemeyer V, Rosenbaum-Krumme S, Buchbender C, Pöppel T, Brandau W, et al. Malignant pheochromocytoma imaging with [124I]mIBG PET/MR. J Clin Endocrinol Metab. 2012;97(11):3833-4. DOI: 10.1210/jc.2012-1958Hartung-Knemeyer V, Rosenbaum-Krumme S, Buchbender C, Pöppel T, Brandau W, et al. Malignant pheochromocytoma imaging with [124I]mIBG PET/MR. J Clin Endocrinol Metab. 2012;97(11):3833-4. DOI: 10.1210/jc.2012-1958Cistaro A, Quartuccio N, Caobelli F, Piccardo A, Paratore R, et al. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma. Nucl Med Rev Cent East Eur. 2015;18(2):102-6. DOI: 10.5603/NMR.2015.0024Cistaro A, Quartuccio N, Caobelli F, Piccardo A, Paratore R, et al. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma. Nucl Med Rev Cent East Eur. 2015;18(2):102-6. DOI: 10.5603/NMR.2015.0024Francis I.R., Mayo-Smith W.W. Adrenal Imaging. In: Hodler J., Kubik-Huch R., von Schulthess G. (eds) Diseases of the Abdomen and Pelvis 2018-2021. IDKD Springer Series. Springer, Cham; 2018. DOI: 10.1007/978-3-319-75019-4_9Francis I.R., Mayo-Smith W.W. Adrenal Imaging. In: Hodler J., Kubik-Huch R., von Schulthess G. (eds) Diseases of the Abdomen and Pelvis 2018-2021. IDKD Springer Series. Springer, Cham; 2018. DOI: 10.1007/978-3-319-75019-4_9Mariani-Costantini R, editor. Paraganglioma: A Multidisciplinary Approach [Internet]. Brisbane (AU): Codon Publications; 2019. PMID: 31294937.Mariani-Costantini R, editor. Paraganglioma: A Multidisciplinary Approach [Internet]. Brisbane (AU): Codon Publications; 2019. PMID: 31294937.Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab. 2013;98(1):E162-73. DOI: 10.1210/jc.2012-2975Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab. 2013;98(1):E162-73. DOI: 10.1210/jc.2012-2975Naji M, Zhao C, Welsh SJ, Meades R, Win Z, et al. 68Ga-DOTATATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13(4):769-75. DOI: 10.1007/s11307-010-0396-8Naji M, Zhao C, Welsh SJ, Meades R, Win Z, et al. 68Ga-DOTATATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13(4):769-75. DOI: 10.1007/s11307-010-0396-8Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, et al. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging. 2015;42(1):33-41. DOI: 10.1007/s00259-014-2892-6Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, et al. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging. 2015;42(1):33-41. DOI: 10.1007/s00259-014-2892-6van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;80(4):487-501. DOI: 10.1111/cen.12341van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;80(4):487-501. DOI: 10.1111/cen.12341Rao D, van Berkel A, Piscaer I, Young WF, Gruber L, et al. Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2019:jc.2018-02355. DOI: 10.1210/jc.2018-02355. Epub ahead of printRao D, van Berkel A, Piscaer I, Young WF, Gruber L, et al. Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2019:jc.2018-02355. DOI: 10.1210/jc.2018-02355. Epub ahead of printVyakaranam AR, Crona J, Norlén O, Granberg D, GarskeRomán U, et al. Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE. Cancers (Basel). 2019;11(7):909. DOI: 10.3390/cancers11070909Vyakaranam AR, Crona J, Norlén O, Granberg D, GarskeRomán U, et al. Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE. Cancers (Basel). 2019;11(7):909. DOI: 10.3390/cancers11070909Granberg D, Juhlin CC, Falhammar H. Metastatic Pheochromocytomas and Abdominal Paragangliomas. J Clin Endocrinol Metab. 2021;106(5):e1937-e1952. DOI: 10.1210/clinem/dgaa982Granberg D, Juhlin CC, Falhammar H. Metastatic Pheochromocytomas and Abdominal Paragangliomas. J Clin Endocrinol Metab. 2021;106(5):e1937-e1952. DOI: 10.1210/clinem/dgaa982Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. Th e treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20(11):648-58. DOI: 10.1007/BF03348026Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. Th e treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20(11):648-58. DOI: 10.1007/BF03348026Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(25):4162-8. DOI: 10.1200/JCO.2008.21.3496Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(25):4162-8. DOI: 10.1200/JCO.2008.21.3496Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, et al. Efficacy and Safety of High-Specifi c-Activity 131I-MIBG Th erapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 2019;60(5):623-630. DOI: 10.2967/jnumed.118.217463Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, et al. Efficacy and Safety of High-Specifi c-Activity 131I-MIBG Th erapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 2019;60(5):623-630. DOI: 10.2967/jnumed.118.217463Barrett JA, Joyal JL, Hillier SM, Maresca KP, Femia FJ, et al. Comparison of high-specifi c-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm. 2010;25(3):299-308. DOI: 10.1089/cbr.2009.0695Barrett JA, Joyal JL, Hillier SM, Maresca KP, Femia FJ, et al. Comparison of high-specifi c-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm. 2010;25(3):299-308. DOI: 10.1089/cbr.2009.0695Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley AM, et al. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. J Surg Oncol. 2017;115(4):425-434. DOI: 10.1002/jso.24553Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley AM, et al. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. J Surg Oncol. 2017;115(4):425-434. DOI: 10.1002/jso.24553Ohshima Y, Sudo H, Watanabe S, Nagatsu K, Tsuji AB, et al. Antitumor eff ects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model. Eur J Nucl Med Mol Imaging. 2018;45(6):999-1010. DOI: 10.1007/s00259-017-3919-6Ohshima Y, Sudo H, Watanabe S, Nagatsu K, Tsuji AB, et al. Antitumor eff ects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model. Eur J Nucl Med Mol Imaging. 2018;45(6):999-1010. DOI: 10.1007/s00259-017-3919-6Chauhan A, El-Khouli R, Waits T, Agrawal R, Siddiqui F, et al. Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients. Oncotarget. 2020;11(32):3061-3068. DOI: 10.18632/oncotarget.27695Chauhan A, El-Khouli R, Waits T, Agrawal R, Siddiqui F, et al. Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients. Oncotarget. 2020;11(32):3061-3068. DOI: 10.18632/oncotarget.27695Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. Th e role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal fi ndings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51(6):875-82. DOI: 10.2967/jnumed.109.066134Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. Th e role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal fi ndings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51(6):875-82. DOI: 10.2967/jnumed.109.066134Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. J Nucl Med. 2019;60(3):369-376. DOI: 10.2967/jnumed.118.211706Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. J Nucl Med. 2019;60(3):369-376. DOI: 10.2967/jnumed.118.211706Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364-72. DOI: 10.2967/jnumed.112.111724Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364-72. DOI: 10.2967/jnumed.112.111724Gild ML, Naik N, Hoang J, Hsiao E, McGrath RT, et al. Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol (Oxf). 2018;89(2):139-147. DOI: 10.1111/cen.13737Gild ML, Naik N, Hoang J, Hsiao E, McGrath RT, et al. Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol (Oxf). 2018;89(2):139-147. DOI: 10.1111/cen.13737Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, et al. (68) Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 2016;16(1):22. DOI: 10.1186/s40644-016-0084-2Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, et al. (68) Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 2016;16(1):22. DOI: 10.1186/s40644-016-0084-2Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, et al. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2015;21(17):3888-95. DOI: 10.1158/1078-0432.CCR-14-2751Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, et al. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2015;21(17):3888-95. DOI: 10.1158/1078-0432.CCR-14-2751Janssen I, Chen CC, Millo CM, Ling A, Taieb D, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43(10):1784-91. DOI: 10.1007/s00259016-3357-xJanssen I, Chen CC, Millo CM, Ling A, Taieb D, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43(10):1784-91. DOI: 10.1007/s00259016-3357-xJanssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, et al. 68GaDOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. J Nucl Med. 2016;57(2):186-91. DOI: 10.2967/jnumed.115.161018Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, et al. 68GaDOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. J Nucl Med. 2016;57(2):186-91. DOI: 10.2967/jnumed.115.161018Janssen I, Chen CC, Zhuang Z, Millo CM, Wolf KI, et al. Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. J Nucl Med. 2017;58(8):1236-1242. DOI: 10.2967/jnumed.116.187690Janssen I, Chen CC, Zhuang Z, Millo CM, Wolf KI, et al. Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. J Nucl Med. 2017;58(8):1236-1242. DOI: 10.2967/jnumed.116.187690Jha A, Ling A, Millo C, Gupta G, Viana B, et al. Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging. 2018;45(5):787-797. DOI: 10.1007/s00259-017-3896-9Jha A, Ling A, Millo C, Gupta G, Viana B, et al. Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging. 2018;45(5):787-797. DOI: 10.1007/s00259-017-3896-9Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, et al. Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Front Oncol. 2019;9:53. DOI: 10.3389/fonc.2019.00053Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, et al. Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Front Oncol. 2019;9:53. DOI: 10.3389/fonc.2019.00053Jha A, Ling A, Millo C, Chen C, Gonzales M, et al. 2019b Diagnostic performance of PET/CT utilizing 68Ga-DOTATATE, 18F-FDG, 18F-DOPA, and 18F-FDA, and anatomic imaging in the detection of sporadic primary pheochromocytoma - A comparative prospective study. Journal of Nuclear Medicine. 2019:439.Jha A, Ling A, Millo C, Chen C, Gonzales M, et al. 2019b Diagnostic performance of PET/CT utilizing 68Ga-DOTATATE, 18F-FDG, 18F-DOPA, and 18F-FDA, and anatomic imaging in the detection of sporadic primary pheochromocytoma - A comparative prospective study. Journal of Nuclear Medicine. 2019:439.Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, et al. A retrospective comparison between 68Ga-DOTA-TOC PET/ CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40(12):18008. DOI: 10.1007/s00259-013-2548-yKroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, et al. A retrospective comparison between 68Ga-DOTA-TOC PET/ CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40(12):18008. DOI: 10.1007/s00259-013-2548-yHerrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, et al. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician’s perspective. J Nucl Med. 2015;56(1):70-5. DOI: 10.2967/jnumed.114.148247Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, et al. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician’s perspective. J Nucl Med. 2015;56(1):70-5. DOI: 10.2967/jnumed.114.148247McGowan A, An JY, Tanakchi S, Maruf M, Muthigi A, et al. Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline SDH-B Mutation. Urol Case Rep. 2017;13:107-109. DOI: 10.1016/j.eucr.2017.03.017McGowan A, An JY, Tanakchi S, Maruf M, Muthigi A, et al. Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline SDH-B Mutation. Urol Case Rep. 2017;13:107-109. DOI: 10.1016/j.eucr.2017.03.017Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, et al. Biodistribution and radiation dose estimates for 68GaDOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46(3):677-685. DOI: 10.1007/s00259-018-4193-yKrebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, et al. Biodistribution and radiation dose estimates for 68GaDOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46(3):677-685. DOI: 10.1007/s00259-018-4193-yZhu W, Cheng Y, Wang X, Yao S, Bai C, et al. Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Diff erentiated Neuroendocrine Tumors: A Prospective Study. J Nucl Med. 2020;61(6):897-903. DOI: 10.2967/jnumed.119.235093Zhu W, Cheng Y, Wang X, Yao S, Bai C, et al. Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Diff erentiated Neuroendocrine Tumors: A Prospective Study. J Nucl Med. 2020;61(6):897-903. DOI: 10.2967/jnumed.119.235093Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-135. DOI: 10.1056/NEJMoa1607427Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-135. DOI: 10.1056/NEJMoa1607427Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, et al. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177LuDotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018;36(25):2578-2584. DOI: 10.1200/JCO.2018.78.5865Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, et al. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177LuDotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018;36(25):2578-2584. DOI: 10.1200/JCO.2018.78.5865Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, et al. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617-4624. DOI: 10.1158/1078-0432.CCR-16-2743Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, et al. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617-4624. DOI: 10.1158/1078-0432.CCR-16-2743Yadav MP, Ballal S, Bal C. Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas. EJNMMI Res. 2019;9(1):13. DOI: 10.1186/s13550-019-0484-yYadav MP, Ballal S, Bal C. Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas. EJNMMI Res. 2019;9(1):13. DOI: 10.1186/s13550-019-0484-yKong G, Grozinsky-Glasberg S, Hofman MS, Callahan J, Meirovitz A, et al. Efficacy of Peptide Receptor Radionuclide Th erapy for Functional Metastatic Paraganglioma and Pheochromocytoma. J Clin Endocrinol Metab. 2017;102(9):3278-3287. DOI: 10.1210/jc.2017-00816Kong G, Grozinsky-Glasberg S, Hofman MS, Callahan J, Meirovitz A, et al. Efficacy of Peptide Receptor Radionuclide Th erapy for Functional Metastatic Paraganglioma and Pheochromocytoma. J Clin Endocrinol Metab. 2017;102(9):3278-3287. DOI: 10.1210/jc.2017-00816Zandee WT, Feelders RA, Smit Duijzentkunst DA, Hofl and J, Metselaar RM, et al. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Eur J Endocrinol. 2019;181(1):45-53. DOI: 10.1530/EJE-18-0901Zandee WT, Feelders RA, Smit Duijzentkunst DA, Hofl and J, Metselaar RM, et al. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Eur J Endocrinol. 2019;181(1):45-53. DOI: 10.1530/EJE-18-0901Satapathy S, Mittal BR, Bhansali A. ‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis’. Clin Endocrinol (Oxf). 2019;91(6):718727. DOI: 10.1111/cen.14106Satapathy S, Mittal BR, Bhansali A. ‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis’. Clin Endocrinol (Oxf). 2019;91(6):718727. DOI: 10.1111/cen.14106Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95(3):289-300. DOI: 10.1016/j.diii.2013.07.006Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95(3):289-300. DOI: 10.1016/j.diii.2013.07.006Lau J, Jacobson O, Niu G, Lin KS, Bénard F, Chen X. Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Th erapies. Bioconjug Chem. 2019;30(3):487-502. DOI: 10.1021/acs.bioconjchem.8b00919Lau J, Jacobson O, Niu G, Lin KS, Bénard F, Chen X. Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Th erapies. Bioconjug Chem. 2019;30(3):487-502. DOI: 10.1021/acs.bioconjchem.8b00919Bandara N, Jacobson O, Mpoy C, Chen X, Rogers BE. Novel Structural Modifi cation Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Th eranostic Agent. Bioconjug Chem. 2018;29(7):2448-2454. DOI: 10.1021/acs.bioconjchem.8b00341Bandara N, Jacobson O, Mpoy C, Chen X, Rogers BE. Novel Structural Modifi cation Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Th eranostic Agent. Bioconjug Chem. 2018;29(7):2448-2454. DOI: 10.1021/acs.bioconjchem.8b00341Wang H, Cheng Y, Zhang J, Zang J, Li H, et al. Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study. Th eranostics. 2018;8(12):3308-3316. DOI: 10.7150/thno.25919Wang H, Cheng Y, Zhang J, Zang J, Li H, et al. Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study. Th eranostics. 2018;8(12):3308-3316. DOI: 10.7150/thno.25919van Berkel A, Rao JU, Kusters B, Demir T, Visser E, et al. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. J Nucl Med. 2014;55(8):1253-9. DOI: 10.2967/jnumed.114.137034van Berkel A, Rao JU, Kusters B, Demir T, Visser E, et al. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. J Nucl Med. 2014;55(8):1253-9. DOI: 10.2967/jnumed.114.137034Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol. 1999;173(1):25-9. DOI: 10.2214/ajr.173.1.10397094Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol. 1999;173(1):25-9. DOI: 10.2214/ajr.173.1.10397094Kim SJ, Lee SW, Pak K, Kim IJ, Kim K. Diagnostic accuracy of 18F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91(1086):20170520. DOI: 10.1259/bjr.20170520Kim SJ, Lee SW, Pak K, Kim IJ, Kim K. Diagnostic accuracy of 18F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91(1086):20170520. DOI: 10.1259/bjr.20170520Ma G, Zhang X, Wang M, Xu X, Xu B, Guan Z. Role of 18F-FDG PET/CT in the diff erential diagnosis of primary benign and malignant unilateral adrenal tumors. Quant Imaging Med Surg. 2021;11(5):2013-2018. DOI: 10.21037/qims20-875Ma G, Zhang X, Wang M, Xu X, Xu B, Guan Z. Role of 18F-FDG PET/CT in the diff erential diagnosis of primary benign and malignant unilateral adrenal tumors. Quant Imaging Med Surg. 2021;11(5):2013-2018. DOI: 10.21037/qims20-875Claimon A, Tantranont N, Claimon T. 18F-fl uoro-2-deoxy-Dglucose positron emission tomography/computed tomography for preoperative planning in a rare case of hyperfunctional bilateral adrenocortical carcinoma and review of literatures. World J Nucl Med. 2020;19(3):301-305. DOI: 10.4103/wjnm.WJNM_86_19Claimon A, Tantranont N, Claimon T. 18F-fl uoro-2-deoxy-Dglucose positron emission tomography/computed tomography for preoperative planning in a rare case of hyperfunctional bilateral adrenocortical carcinoma and review of literatures. World J Nucl Med. 2020;19(3):301-305. DOI: 10.4103/wjnm.WJNM_86_19Ecénarro-Montiel A, Baleato-González S, Santiago-Pérez MI, Sánchez-González J, Montesinos P, García-Figueiras R. Using the modifi ed Dixon technique to evaluate incidental adrenal lesions on 3T MRI. Radiologia (Engl Ed). 2018;60(6):485-492. DOI: 10.1016/j.rx.2018.06.001Ecénarro-Montiel A, Baleato-González S, Santiago-Pérez MI, Sánchez-González J, Montesinos P, García-Figueiras R. Using the modifi ed Dixon technique to evaluate incidental adrenal lesions on 3T MRI. Radiologia (Engl Ed). 2018;60(6):485-492. DOI: 10.1016/j.rx.2018.06.001Dong A, Cui Y, Wang Y, Zuo C, Bai Y. (18)F-FDG PET/CT of adrenal lesions. AJR Am J Roentgenol. 2014;203(2):245-52. DOI: 10.2214/AJR.13.11793Dong A, Cui Y, Wang Y, Zuo C, Bai Y. (18)F-FDG PET/CT of adrenal lesions. AJR Am J Roentgenol. 2014;203(2):245-52. DOI: 10.2214/AJR.13.11793Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, et al. Diagnostic and prognostic value of 18-fl uorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006;91(3):920-5. DOI: 10.1210/jc.2005-1540Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, et al. Diagnostic and prognostic value of 18-fl uorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006;91(3):920-5. DOI: 10.1210/jc.2005-1540Ardito A, Massaglia C, Pelosi E, Zaggia B, Basile V, et al. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. Eur J Endocrinol. 2015;173(6):749-56. DOI: 10.1530/EJE-15-0707Ardito A, Massaglia C, Pelosi E, Zaggia B, Basile V, et al. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. Eur J Endocrinol. 2015;173(6):749-56. DOI: 10.1530/EJE-15-0707Papadakis GZ, Millo C, Stratakis CA. Benign hormonesecreting adenoma within a larger adrenocortical mass showing intensely increased activity on 18F-FDG PET/CT. Endocrine. 2016;54(1):269-270. DOI: 10.1007/s12020-016-0969-7Papadakis GZ, Millo C, Stratakis CA. Benign hormonesecreting adenoma within a larger adrenocortical mass showing intensely increased activity on 18F-FDG PET/CT. Endocrine. 2016;54(1):269-270. DOI: 10.1007/s12020-016-0969-7Shimizu A, Oriuchi N, Tsushima Y, Higuchi T, Aoki J, Endo K. High [18F] 2-fl uoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing’s syndrome. Ann Nucl Med. 2003;17(5):403-6. DOI: 10.1007/BF03006609Shimizu A, Oriuchi N, Tsushima Y, Higuchi T, Aoki J, Endo K. High [18F] 2-fl uoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing’s syndrome. Ann Nucl Med. 2003;17(5):403-6. DOI: 10.1007/BF03006609Ansquer C, Scigliano S, Mirallié E, Taïeb D, Brunaud L, et al. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. Eur J Nucl Med Mol Imaging. 2010;37(9):1669-78. DOI: 10.1007/s00259-010-1471-8Ansquer C, Scigliano S, Mirallié E, Taïeb D, Brunaud L, et al. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. Eur J Nucl Med Mol Imaging. 2010;37(9):1669-78. DOI: 10.1007/s00259-010-1471-8Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fl uorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700-8. DOI: 10.1093/jnci/djs188Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fl uorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700-8. DOI: 10.1093/jnci/djs188Tiwari A, Shah N, Sarathi V, Malhotra G, Bakshi G, et al. Genetic status determines 18 F-FDG uptake in pheochromocytoma/ paraganglioma. J Med Imaging Radiat Oncol. 2017;61(6):745752. DOI: 10.1111/1754-9485.12620Tiwari A, Shah N, Sarathi V, Malhotra G, Bakshi G, et al. Genetic status determines 18 F-FDG uptake in pheochromocytoma/ paraganglioma. J Med Imaging Radiat Oncol. 2017;61(6):745752. DOI: 10.1111/1754-9485.12620Kundu S, Kand P, Basu S. Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fl uorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role? South Asian J Cancer. 2017;6(1):31-34. DOI: 10.4103/2278-330X.202556Kundu S, Kand P, Basu S. Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fl uorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role? South Asian J Cancer. 2017;6(1):31-34. DOI: 10.4103/2278-330X.202556Kunikowska J, Matyskiel R, Toutounchi S, Grabowska-Derlatka L, Koperski L, Królicki L. What parameters from 18F-FDG PET/ CT are useful in evaluation of adrenal lesions? Eur J Nucl Med Mol Imaging. 2014;41(12):2273-80. DOI: 10.1007/s00259-0142844-1Kunikowska J, Matyskiel R, Toutounchi S, Grabowska-Derlatka L, Koperski L, Królicki L. What parameters from 18F-FDG PET/ CT are useful in evaluation of adrenal lesions? Eur J Nucl Med Mol Imaging. 2014;41(12):2273-80. DOI: 10.1007/s00259-0142844-1Patel D, Mehta A, Nilubol N, Dieckmann W, Pacak K, Kebebew E. Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas. Ann Surg. 2016;263(3):582-7. DOI: 10.1097/SLA.0000000000001018Patel D, Mehta A, Nilubol N, Dieckmann W, Pacak K, Kebebew E. Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas. Ann Surg. 2016;263(3):582-7. DOI: 10.1097/SLA.0000000000001018Nockel P, El Lakis M, Gaitanidis A, Merkel R, Patel D, et al. Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. Ann Surg. 2019;269(4):741-747. DOI: 10.1097/SLA.0000000000002671Nockel P, El Lakis M, Gaitanidis A, Merkel R, Patel D, et al. Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. Ann Surg. 2019;269(4):741-747. DOI: 10.1097/SLA.0000000000002671Koopman D, van Dalen JA, Stigt JA, Slump CH, Knollema S, Jager PL. Current generation time-of-fl ight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands. Ann Nucl Med. 2016;30(2):145-52. DOI: 10.1007/s12149-015-1041-zKoopman D, van Dalen JA, Stigt JA, Slump CH, Knollema S, Jager PL. Current generation time-of-fl ight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands. Ann Nucl Med. 2016;30(2):145-52. DOI: 10.1007/s12149-015-1041-zChondrogiannis S, Marzola MC, Al-Nahhas A, Venkatanarayana TD, Mazza A, et al. Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl Med Commun. 2013;34(12):1141-9. DOI: 10.1097/MNM.0000000000000008Chondrogiannis S, Marzola MC, Al-Nahhas A, Venkatanarayana TD, Mazza A, et al. Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl Med Commun. 2013;34(12):1141-9. DOI: 10.1097/MNM.0000000000000008Santhanam P, Taïeb D. Role of (18) F-FDOPA PET/ CT imaging in endocrinology. Clin Endocrinol (Oxf). 2014;81(6):789-98. DOI: 10.1111/cen.12566Santhanam P, Taïeb D. Role of (18) F-FDOPA PET/ CT imaging in endocrinology. Clin Endocrinol (Oxf). 2014;81(6):789-98. DOI: 10.1111/cen.12566Noordzij W, Glaudemans AWJM, Schaafsma M, van der Horst-Schrivers ANA, Slart RHJA, et al. Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls. Eur J Nucl Med Mol Imaging. 2019;46(7):1560-1566. DOI: 10.1007/s00259-01904332-5Noordzij W, Glaudemans AWJM, Schaafsma M, van der Horst-Schrivers ANA, Slart RHJA, et al. Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls. Eur J Nucl Med Mol Imaging. 2019;46(7):1560-1566. DOI: 10.1007/s00259-01904332-5Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, et al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging. 2016;43(7):124857. DOI: 10.1007/s00259-015-3268-2Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, et al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging. 2016;43(7):124857. DOI: 10.1007/s00259-015-3268-2Taïeb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019;26(11):R627-R652. DOI: 10.1530/ERC-19-0165Taïeb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019;26(11):R627-R652. DOI: 10.1530/ERC-19-0165Nölting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, et al. Current Management of Pheochromocytoma/ Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers (Basel). 2019;11(10):1505. DOI: 10.3390/cancers11101505Nölting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, et al. Current Management of Pheochromocytoma/ Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers (Basel). 2019;11(10):1505. DOI: 10.3390/cancers11101505Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46(10):2112-2137. DOI: 10.1007/s00259019-04398-1Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46(10):2112-2137. DOI: 10.1007/s00259019-04398-1Tepede AA, Welch J, Lee M, Mandl A, Agarwal SK, et al. 18F-FDOPA PET/CT accurately identifi es MEN1-associated pheochromocytoma. Endocrinol Diabetes Metab Case Rep. 2020;2020:19-0156. DOI: 10.1530/EDM-19-0156. Epub ahead of printTepede AA, Welch J, Lee M, Mandl A, Agarwal SK, et al. 18F-FDOPA PET/CT accurately identifi es MEN1-associated pheochromocytoma. Endocrinol Diabetes Metab Case Rep. 2020;2020:19-0156. DOI: 10.1530/EDM-19-0156. Epub ahead of printTimmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, et al. Comparison of 18F-fl uoro-L-DOPA, 18F-fl uorodeoxyglucose, and 18F-fl uorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):475767. DOI: 10.1210/jc.2009-1248Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, et al. Comparison of 18F-fl uoro-L-DOPA, 18F-fl uorodeoxyglucose, and 18F-fl uorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):475767. DOI: 10.1210/jc.2009-1248Timmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, et al. Use of 6-[18F]-fl uorodopamine positron emission tomography (PET) as fi rst-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf). 2009;71(1):11-7. DOI: 10.1111/j.1365-2265.2008.03496.xTimmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, et al. Use of 6-[18F]-fl uorodopamine positron emission tomography (PET) as fi rst-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf). 2009;71(1):11-7. DOI: 10.1111/j.1365-2265.2008.03496.xTimmers HJ, Carrasquillo JA, Whatley M, Eisenhofer G, Chen CC, et al. Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fl uorodopamine PET. J Nucl Med. 2007;48(12):1940-4. DOI: 10.2967/jnumed.107.043281Timmers HJ, Carrasquillo JA, Whatley M, Eisenhofer G, Chen CC, et al. Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fl uorodopamine PET. J Nucl Med. 2007;48(12):1940-4. DOI: 10.2967/jnumed.107.043281Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, et al. Th e role of 6-[18F]fl uorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007;156(4):483-7. DOI: 10.1530/EJE-06-0712Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, et al. Th e role of 6-[18F]fl uorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007;156(4):483-7. DOI: 10.1530/EJE-06-0712Pacak K, Eisenhofer G, Ilias I. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones (Athens). 2009;8(2):111-6. DOI: 10.14310/horm.2002.1227Pacak K, Eisenhofer G, Ilias I. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones (Athens). 2009;8(2):111-6. DOI: 10.14310/horm.2002.1227Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med. 2013;54(6):903-12. DOI: 10.2967/jnumed.112.112201Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med. 2013;54(6):903-12. DOI: 10.2967/jnumed.112.112201Chalkidou A, Landau DB, Odell EW, Cornelius VR, O’Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fl uorothymidine uptake in patients with cancer: A systematic review and metaanalysis. Eur J Cancer. 2012;48(18):3499-513. DOI: 10.1016/j.ejca.2012.05.001Chalkidou A, Landau DB, Odell EW, Cornelius VR, O’Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fl uorothymidine uptake in patients with cancer: A systematic review and metaanalysis. Eur J Cancer. 2012;48(18):3499-513. DOI: 10.1016/j.ejca.2012.05.001Giammarile F, Billotey C, Lombard-Bohas C, Le Bars D, Bournaud C, et al. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-diff erentiated gastroentero-pancreatic endocrine tumours. Nucl Med Commun. 2011;32(2):91-7. DOI: 10.1097/MNM.0b013e3283412143Giammarile F, Billotey C, Lombard-Bohas C, Le Bars D, Bournaud C, et al. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-diff erentiated gastroentero-pancreatic endocrine tumours. Nucl Med Commun. 2011;32(2):91-7. DOI: 10.1097/MNM.0b013e3283412143Nakajo M, Nakajo M, Kajiya Y, Jinguji M, Mori S, et al. High FDG and low FLT uptake in a thyroid papillary carcinoma incidentally discovered by FDG PET/CT. Clin Nucl Med. 2012;37(6):607-8. DOI: 10.1097/RLU.0b013e318252d80fNakajo M, Nakajo M, Kajiya Y, Jinguji M, Mori S, et al. High FDG and low FLT uptake in a thyroid papillary carcinoma incidentally discovered by FDG PET/CT. Clin Nucl Med. 2012;37(6):607-8. DOI: 10.1097/RLU.0b013e318252d80fNakajo M, Nakajo M, Jinguji M, Tani A, Kajiya Y, et al. Diagnosis of metastases from postoperative diff erentiated thyroid cancer: comparison between FDG and FLT PET/CT studies. Radiology. 2013;267(3):891-901. DOI: 10.1148/radiol.13121546Nakajo M, Nakajo M, Jinguji M, Tani A, Kajiya Y, et al. Diagnosis of metastases from postoperative diff erentiated thyroid cancer: comparison between FDG and FLT PET/CT studies. Radiology. 2013;267(3):891-901. DOI: 10.1148/radiol.13121546Blanchet EM, Taieb D, Millo C, Martucci V, Chen CC, et al. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. J Nucl Med. 2015;56(12):184954. DOI: 10.2967/jnumed.115.159061Blanchet EM, Taieb D, Millo C, Martucci V, Chen CC, et al. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. J Nucl Med. 2015;56(12):184954. DOI: 10.2967/jnumed.115.159061Yu M, Bozek J, Lamoy M, Guaraldi M, Silva P, et al. Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging. 2011;4(4):435-43. DOI: 10.1161/CIRCIMAGING.110.962126Yu M, Bozek J, Lamoy M, Guaraldi M, Silva P, et al. Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging. 2011;4(4):435-43. DOI: 10.1161/CIRCIMAGING.110.962126Yu M, Bozek J, Lamoy M, Kagan M, Benites P, et al. LMI1195 PET imaging in evaluation of regional cardiac sympathetic denervation and its potential role in antiarrhythmic drug treatment. Eur J Nucl Med Mol Imaging. 2012;39(12):1910-9. DOI: 10.1007/s00259-012-2204-yYu M, Bozek J, Lamoy M, Kagan M, Benites P, et al. LMI1195 PET imaging in evaluation of regional cardiac sympathetic denervation and its potential role in antiarrhythmic drug treatment. Eur J Nucl Med Mol Imaging. 2012;39(12):1910-9. DOI: 10.1007/s00259-012-2204-yGaertner FC, Wiedemann T, Yousefi BH, Lee M, Repokis I, et al. Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model. J Nucl Med. 2013;54(12):2111-7. DOI: 10.2967/jnumed.113.119966Gaertner FC, Wiedemann T, Yousefi BH, Lee M, Repokis I, et al. Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model. J Nucl Med. 2013;54(12):2111-7. DOI: 10.2967/jnumed.113.119966Rischpler C, Schlitter A, Herz M, Yousefi B, Von Werder A, Tauber R. First experience using LMI1195 PET in patients with the suspicion of pheochromocytoma or paraganglioma. Journal of Nuclear Medicine. 2018:59.Rischpler C, Schlitter A, Herz M, Yousefi B, Von Werder A, Tauber R. First experience using LMI1195 PET in patients with the suspicion of pheochromocytoma or paraganglioma. Journal of Nuclear Medicine. 2018:59.Yen RF, Wu VC, Liu KL, Cheng MF, Wu YW, et al. 131I-6betaiodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med. 2009;50(10):1631-7. DOI: 10.2967/jnumed.109.064873Yen RF, Wu VC, Liu KL, Cheng MF, Wu YW, et al. 131I-6betaiodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med. 2009;50(10):1631-7. DOI: 10.2967/jnumed.109.064873Chen YC, Chiu JS, Wang YF. NP-59 SPECT/CT imaging in stage 1 hypertensive and atypical primary aldosteronism: a 5-year retrospective analysis of clinicolaboratory and imaging features. Scientifi cWorldJournal. 2013;2013:317934. DOI: 10.1155/2013/317934Chen YC, Chiu JS, Wang YF. NP-59 SPECT/CT imaging in stage 1 hypertensive and atypical primary aldosteronism: a 5-year retrospective analysis of clinicolaboratory and imaging features. Scientifi cWorldJournal. 2013;2013:317934. DOI: 10.1155/2013/317934Chen YC, Su YC, Wei CK, Chiu JS, Tseng CE, et al. Diagnostic value of I-131 NP-59 SPECT/CT scintigraphy in patients with subclinical or atypical features of primary aldosteronism. J Biomed Biotechnol. 2011;2011:209787. DOI: 10.1155/2011/209787Chen YC, Su YC, Wei CK, Chiu JS, Tseng CE, et al. Diagnostic value of I-131 NP-59 SPECT/CT scintigraphy in patients with subclinical or atypical features of primary aldosteronism. J Biomed Biotechnol. 2011;2011:209787. DOI: 10.1155/2011/209787Lee J, Ha J, Lee SK, Park HL, Kim SH, et al. Feasibility of Iodine-131 6β-Methyl-Iodo-19 Norcholesterol (NP-59) Scintigraphy to Complement Adrenal Venous Sampling in Management of Primary Aldosteronism: A Case Series. Int J Gen Med. 2021;14:673-680. DOI: 10.2147/IJGM.S288774Lee J, Ha J, Lee SK, Park HL, Kim SH, et al. Feasibility of Iodine-131 6β-Methyl-Iodo-19 Norcholesterol (NP-59) Scintigraphy to Complement Adrenal Venous Sampling in Management of Primary Aldosteronism: A Case Series. Int J Gen Med. 2021;14:673-680. DOI: 10.2147/IJGM.S288774Prado-Wohlwend S; Grupo de Trabajo de Endocrinología de la SEMNIM. Functional imaging of adrenal cortex. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020;39(6):393-404. DOI: 10.1016/j.remn.2020.08.010.Prado-Wohlwend S; Grupo de Trabajo de Endocrinología de la SEMNIM. Functional imaging of adrenal cortex. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020;39(6):393-404. DOI: 10.1016/j.remn.2020.08.010.Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984;310(22):1415-21. DOI: 10.1056/NEJM198405313102202Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984;310(22):1415-21. DOI: 10.1056/NEJM198405313102202Bergström M, Bonasera TA, Lu L, Bergström E, Backlin C, et al. In vitro and in vivo primate evaluation of carbon-11etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med. 1998;39(6):982-9. PMID: 9627330Bergström M, Bonasera TA, Lu L, Bergström E, Backlin C, et al. In vitro and in vivo primate evaluation of carbon-11etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med. 1998;39(6):982-9. PMID: 9627330Khan TS, Sundin A, Juhlin C, Långström B, Bergström M, Eriksson B. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging. 2003;30(3):403-10. DOI: 10.1007/s00259-002-1025-9Khan TS, Sundin A, Juhlin C, Långström B, Bergström M, Eriksson B. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging. 2003;30(3):403-10. DOI: 10.1007/s00259-002-1025-9Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, et al. Evaluation of the sensitivity and specifi city of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab. 2012;97(1):100-9. DOI: 10.1210/jc.2011-1537Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, et al. Evaluation of the sensitivity and specifi city of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab. 2012;97(1):100-9. DOI: 10.1210/jc.2011-1537O’Shea PM, O’Donoghue D, Bashari W, Senanayake R, Joyce MB, et al. 11 C-Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice. Clin Endocrinol (Oxf). 2019;90(5):670-679. DOI: 10.1111/cen.13942O’Shea PM, O’Donoghue D, Bashari W, Senanayake R, Joyce MB, et al. 11 C-Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice. Clin Endocrinol (Oxf). 2019;90(5):670-679. DOI: 10.1111/cen.13942Soinio M, Luukkonen AK, Seppänen M, Kemppainen J, Seppänen J, et al. Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. Eur J Endocrinol. 2020;183(6):539-550. DOI: 10.1530/EJE-20-0532Soinio M, Luukkonen AK, Seppänen M, Kemppainen J, Seppänen J, et al. Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. Eur J Endocrinol. 2020;183(6):539-550. DOI: 10.1530/EJE-20-0532Hennings J, Sundin A, Hägg A, Hellman P. 11C-metomidate positron emission tomography aft er dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism. Langenbecks Arch Surg. 2010;395(7):963-7. DOI: 10.1007/s00423-010-0681-7Hennings J, Sundin A, Hägg A, Hellman P. 11C-metomidate positron emission tomography aft er dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism. Langenbecks Arch Surg. 2010;395(7):963-7. DOI: 10.1007/s00423-010-0681-7Mendichovszky IA, Powlson AS, Manavaki R, Aigbirhio FI, Cheow H, et al. Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT. Diagnostics (Basel). 2016;6(4):42. DOI: 10.3390/diagnostics6040042Mendichovszky IA, Powlson AS, Manavaki R, Aigbirhio FI, Cheow H, et al. Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT. Diagnostics (Basel). 2016;6(4):42. DOI: 10.3390/diagnostics6040042Powlson AS, Gurnell M, Brown MJ. Nuclear imaging in the diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes. 2015;22(3):150-6. DOI: 10.1097/MED.0000000000000148Powlson AS, Gurnell M, Brown MJ. Nuclear imaging in the diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes. 2015;22(3):150-6. DOI: 10.1097/MED.0000000000000148Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J,et al. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med. 2000;41(2):275-82. PMID: 10688111Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J,et al. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med. 2000;41(2):275-82. PMID: 10688111Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, et al. Imaging of adrenal incidentalomas with PET using (11) C-metomidate and (18)F-FDG. J Nucl Med. 2004;45(6):972-9. PMID: 15181132Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, et al. Imaging of adrenal incidentalomas with PET using (11) C-metomidate and (18)F-FDG. J Nucl Med. 2004;45(6):972-9. PMID: 15181132Zolle IM, Berger ML, Hammerschmidt F, Hahner S, Schirbel A, Peric-Simov B. New selective inhibitors of steroid 11betahydroxylation in the adrenal cortex. Synthesis and structureactivity relationship of potent etomidate analogues. J Med Chem. 2008;51(7):2244-53. DOI: 10.1021/jm800012wZolle IM, Berger ML, Hammerschmidt F, Hahner S, Schirbel A, Peric-Simov B. New selective inhibitors of steroid 11betahydroxylation in the adrenal cortex. Synthesis and structureactivity relationship of potent etomidate analogues. J Med Chem. 2008;51(7):2244-53. DOI: 10.1021/jm800012wErlandsson M, Karimi F, Lindhe O, Långström B. (18) F-labelled metomidate analogues as adrenocortical imaging agents. Nucl Med Biol. 2009;36(4):435-45. DOI: 10.1016/j.nucmedbio.2009.01.014Erlandsson M, Karimi F, Lindhe O, Långström B. (18) F-labelled metomidate analogues as adrenocortical imaging agents. Nucl Med Biol. 2009;36(4):435-45. DOI: 10.1016/j.nucmedbio.2009.01.014Bongarzone S, Basagni F, Sementa T, Singh N, Gakpetor C, et al. Development of [18F]FAMTO: A novel fl uorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands. Nucl Med Biol. 2019;68-69:14-21. DOI: 10.1016/j.nucmedbio.2018.11.002Bongarzone S, Basagni F, Sementa T, Singh N, Gakpetor C, et al. Development of [18F]FAMTO: A novel fl uorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands. Nucl Med Biol. 2019;68-69:14-21. DOI: 10.1016/j.nucmedbio.2018.11.002Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, et al. Functional characterization of adrenal lesions using [123I] IMTO-SPECT/CT. J Clin Endocrinol Metab. 2013;98(4):150818. DOI: 10.1210/jc.2012-3045Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, et al. Functional characterization of adrenal lesions using [123I] IMTO-SPECT/CT. J Clin Endocrinol Metab. 2013;98(4):150818. DOI: 10.1210/jc.2012-3045Sander K, Gendron T, Cybulska KA, Sirindil F, Zhou J, et al. Development of [18F]AldoView as the First Highly Selective Aldosterone Synthase PET Tracer for Imaging of Primary Hyperaldosteronism. J Med Chem. 2021;64(13):93219329. DOI: 10.1021/acs.jmedchem.1c00539Sander K, Gendron T, Cybulska KA, Sirindil F, Zhou J, et al. Development of [18F]AldoView as the First Highly Selective Aldosterone Synthase PET Tracer for Imaging of Primary Hyperaldosteronism. J Med Chem. 2021;64(13):93219329. DOI: 10.1021/acs.jmedchem.1c00539Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension. 2018;71(2):317-325. DOI: 10.1161/HYPERTENSIONAHA.117.09975Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension. 2018;71(2):317-325. DOI: 10.1161/HYPERTENSIONAHA.117.09975Walenkamp AME, Lapa C, Herrmann K, Wester HJ. CXCR4 Ligands: Th e Next Big Hit? J Nucl Med. 2017;58(Suppl 2):77S-82S. DOI: 10.2967/jnumed.116.186874Walenkamp AME, Lapa C, Herrmann K, Wester HJ. CXCR4 Ligands: Th e Next Big Hit? J Nucl Med. 2017;58(Suppl 2):77S-82S. DOI: 10.2967/jnumed.116.186874Ding J, Zhang Y, Wen J, Zhang H, Wang H, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020;47(11):2656-2665. DOI: 10.1007/s00259-020-04722-0Ding J, Zhang Y, Wen J, Zhang H, Wang H, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020;47(11):2656-2665. DOI: 10.1007/s00259-020-04722-0Cui Y, Zhang Y, Ding J, Wang H, Ma X, et al. A Rare AldosteroneProducing Adenoma Detected by 68Ga-pentixafor PETCT: A Case Report and Literature Review. Front Endocrinol (Lausanne). 2019;10:810. DOI: 10.3389/fendo.2019.00810Cui Y, Zhang Y, Ding J, Wang H, Ma X, et al. A Rare AldosteroneProducing Adenoma Detected by 68Ga-pentixafor PETCT: A Case Report and Literature Review. Front Endocrinol (Lausanne). 2019;10:810. DOI: 10.3389/fendo.2019.00810

The authors declare that there are no conflicts of interest present.